Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy

A combination of two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, given once every 4 or 8 weeks, maintained viral suppression as well as a standard oral antiretroviral therapy (ART) regimen and appeared safe and well-tolerated, according to results from the LATTE 2 trial pr…